Karyopharm Therapeutics Inc (KPTI) — Cash Flow-to-Debt Ratio
Karyopharm Therapeutics Inc (KPTI) has a Cash Flow-to-Debt Ratio of -0.03x as of December 2025, meaning its operating cash flow of $-11.83 Million could theoretically repay 0% of its total liabilities ($401.34 Million) in one year. See KPTI free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Karyopharm Therapeutics Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Karyopharm Therapeutics Inc across 15 annual periods. Also explore how fast is Karyopharm Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Karyopharm Therapeutics Inc (2011–2025)
Year-by-year debt coverage analysis for Karyopharm Therapeutics Inc. For market capitalisation and broader financial context, see Karyopharm Therapeutics Inc (KPTI) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.19x | $-75.37 Million | $401.34 Million | ▲ +48.4% |
| 2024 | -0.36x | $-127.49 Million | $350.44 Million | ▼ -47.8% |
| 2023 | -0.25x | $-92.72 Million | $376.64 Million | ▲ +38.3% |
| 2022 | -0.40x | $-149.55 Million | $374.83 Million | ▼ -43.4% |
| 2021 | -0.28x | $-107.12 Million | $384.98 Million | ▲ +54.4% |
| 2020 | -0.61x | $-160.23 Million | $262.50 Million | ▲ +21.6% |
| 2019 | -0.78x | $-190.82 Million | $245.19 Million | ▲ +22.7% |
| 2018 | -1.01x | $-159.12 Million | $158.02 Million | ▲ +30.6% |
| 2017 | -1.45x | $-73.72 Million | $50.83 Million | ▲ +68.8% |
| 2016 | -4.65x | $-84.39 Million | $18.14 Million | ▲ +15.5% |
| 2015 | -5.51x | $-94.03 Million | $17.08 Million | ▼ -44.9% |
| 2014 | -3.80x | $-51.45 Million | $13.54 Million | ▲ +58.7% |
| 2013 | -9.20x | $-30.29 Million | $3.29 Million | ▼ -1631.6% |
| 2012 | -0.53x | $-15.51 Million | $29.19 Million | ▼ -23.5% |
| 2011 | -0.43x | $-8.55 Million | $19.88 Million | — |